drugset
drugset / Trial / NCT05242445

A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection

NCT05242445 ↗

Phase 1 Completed 11 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of the study is to characterize the pharmacokinetic (PK) profile of cetrelimab administered subcutaneous (SC) and optionally intravenous (IV) in chronic hepatitis B (CHB) participants.

Timeline

Start
2022-04-19
Primary completion
2023-05-09
Completion
2023-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetrelimab Monoclonal antibody — Subcutaneous

Indications

chronic hepatitis B virus infection